MarketCap
Facebook
X
Telegram
Titan Pharmaceuticals ROA Ratio | TTNP
Annual ROA Ratio Titan Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -161.0 | -68.87 | -251.5 | -109.78 | - | -172.84 | -64.02 | -160.66 | 27.51 | -84.89 | -11.52 | 52.71 | -61.14 | -148.8 | -143.81 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 52.71 | -251.5 | -97.04 |
Quarterly ROA Ratio Titan Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -117.99 | -111.36 | -85.25 | -88.63 | -262.76 | -291.91 | -275.96 | -317.99 | -344.21 | -173.51 | -96.25 | -116.12 | -88.68 | -78.19 | -53.58 | -114.56 | -152.08 | -206.53 | -187.42 | -228.81 | -197.26 | -194.45 | -172.84 | -156.31 | -141.38 | -92.97 | -64.02 | -80.26 | -112.81 | -145.4 | -160.66 | -132.03 | -99.0 | 3.65 | 27.51 | 22.71 | 23.14 | -57.92 | -84.89 | -69.89 | -52.86 | -39.73 | -11.52 | -10.39 | -20.04 | 11.49 | 52.71 | 52.72 | 26.66 | -7.77 | -61.14 | -88.38 | -63.97 | -125.44 | -148.8 | -7.87 | -68.41 | -44.16 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 52.72 | -344.21 | -101.44 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Annexon
ANNX
|
-74.47 | $ 4.21 | 4.99 % | $ 653 M |  USA |
 |
AbbVie
ABBV
|
1.36 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-18.7 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
1.78 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
4.39 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-4.95 | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
-15.57 | - | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
27.51 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-14.64 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
14.42 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
0.99 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
6.32 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-82.65 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-142.19 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-56.38 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
13.46 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-56.43 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-81.36 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-221.26 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-29.82 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-72.91 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-41.31 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-10.92 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
-176.62 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-103.3 | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
-13.02 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-2.77 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-28.79 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-6.89 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-29.75 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
0.74 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
26.31 | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
-428.94 | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
13.34 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.77 | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
-26.84 | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
-37.97 | $ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-37.35 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
2.66 | - | - | - |  Russia |
 |
CorMedix
CRMD
|
19.74 | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
12.59 | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
-24.8 | $ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
3.73 | $ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
9.69 | $ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
-3565.14 | - | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-55.1 | $ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
-25.57 | - | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
-74.69 | $ 7.93 | 0.51 % | $ 427 M | USA |